Skip to main content
Premium Trial:

Request an Annual Quote

Prolexys Pharma and Whitehead Collaborate on Chemiproteomics

NEW YORK, Dec. 5 (GenomeWeb News) - Prolexys Pharmaceuticals, formerly Myriad Proteomics, announced today that it is collaborating with the Whitehead Institute to use compounds from Whitehead and Prolexys' HySpec mass spec platform and chemiproteomic techniques to find new oncology targets.


The collaboration will last for two years under the current agreement. Scientists will look to identify compounds with limited toxicology and side effects. Brent Stockwell's lab at Whitehead will provide the compounds and will modify the compounds following the proteomic studies at Prolexys.


Financial terms of the agreement were not disclosed.


The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.